Clinical trial · Interventional
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer
A PhaseⅠStudy to Examine Tolerability and Safety of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and Safety of ONO-7475 in Combination With GnP in Patients With Metastatic Pancreatic Cancer as First-line Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gemcitabine | Drug | Gemcitabine | ALIAS |
| Nab-paclitaxel | Drug | Nab-paclitaxel | ALIAS |
| ONO-4538 | Drug | Nivolumab | ALIAS |
| ONO-7475 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ONO-7475+GnP
- interventionNames
- Drug: ONO-7475
- Drug: Nab-paclitaxel
- Drug: Gemcitabine
- type
- EXPERIMENTAL
- label
- ONO-7475＋ONO-4538＋GnP
- interventionNames
- Drug: ONO-7475
- Drug: ONO-4538
- Drug: Nab-paclitaxel
- Drug: Gemcitabine
Primary outcomes (2)
- measure
- Dose-limiting toxicities (DLT)
- timeFrame
- 28 days
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with metastatic pancreatic cancer 2. Patients have an ECOG performance status of 0 to 1 3. Patients with a life expectancy of at least 6 months Exclusion Criteria: 1. Patients are unable to swallow oral medications 2. Patients with severe complication
References
Publications (0)
Data not yet available